ClinicalTrials.gg
RecruitingNCT06982521ReDiscover-2Updated Nov 5, 2026

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

A Phase 3 interventional study of Zovegalisib and Capivasertib in PIK3CA Mutation, HER2- Negative Breast Cancer and Hormone Receptor Positive Tumor, sponsored by Relay Therapeutics, Inc.. Recruiting at 254 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Relay Therapeutics, Inc. · Phase 3, Interventional, and Treatment

How we know · 8 judgments

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.
Updated Nov 5, 2026First sites in Ireland, Romania and Turkey (Türkiye)23 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
540
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment with a CDK4/6 inhibitor.

02

Conditions studied

  • PIK3CA Mutation
  • HER2- Negative Breast Cancer
  • Hormone Receptor Positive Tumor
  • Breast Cancer
  • Metastatic Breast Cancer
  • Advanced Breast Cancer

Browse trials for

03

In context

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

This study's planned enrollment of 540 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Relay Therapeutics, Inc. is the lead sponsor of 5 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient has performance status of 0-1
  • One or more known primary oncogenic PIK3CA mutation(s)
  • Adult females, pre- and/or , and adult males. Pre-menopausal (and peri-menopausal) women can be enrolled if amenable to treatment with a gonadotropin-releasing hormone (GnRH) agonist. Patients are to have commenced treatment with a GnRH agonist at least 2 weeks prior to randomization and must be willing to continue on it for the duration of the study.
  • or cytologically confirmed diagnosis of HR+/- locally advanced or breast cancer (ABC) with radiological or objective evidence of recurrence or progression; locally advanced disease must not be amenable to resection with curative intent
  • per v1.1 or evaluable bone-only disease.
  • Must have radiological evidence of progression on or after previous treatment for HR+/HER2- ABC with:

    1. At least 1 and no more than 2 lines of endocrine therapy (ET) in the (neo) setting with recurrence on or within 12 months of completion or in the ABC setting
    2. Only 1 prior line of CDK4/6 inhibitor therapy in one of the following settings:

      1. CDK4/6 inhibitor + ET in the ABC setting
      2. CDK4/6 inhibitor therapy in the adjuvant setting if progression occurred during or within 12 months of completion of adjuvant CDK4/6 inhibitor with ET
      3. Patients who progressed during or within 12 months of completion of adjuvant CDK4/6 inhibitor and after receiving CDK4/6 inhibitor therapy in the advanced setting are considered to have had >1 prior line of CDK4/6 inhibitor and are not eligible

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with any of the following:

    1. CDK2 inhibitors. Prior treatment with other CDK inhibitors could be permitted upon discussion and approval from the Sponsor
    2. PIK3, AKT, or mTOR inhibitors or any agent whose mechanism of action is the inhibit the PIK3/AKT/mTOR pathway
    3. Immunotherapy
    4. Antibody drug conjugates
  • Type 1 diabetes, or Type 2 diabetes requiring antihyperglycemic medication, or fasting plasma glucose ≥ 140 mg/dL (7.8 mmol/L), or glycosylated () ≥7.0% (≥ 53 mmol/mol).
  • , uncontrolled cardiovascular disease
  • Any factors that increase the risk of prolongation or risk of arrhythmic events
  • Known active uncontrolled or symptomatic associated with progressive neurological symptoms or requiring ongoing or anticonvulsants for symptomatic control
  • Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease
  • History of to fulvestrant or drugs in a similar class as fulvestrant, zovegalisib, or capivasertib, including their
  • Known activating AKT mutations, loss-of-function PTEN mutations, or loss of PTEN expression resulting in oncogenic pathway activation downstream of PI3K
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
540 participants (estimated)

Study arms

  • Experimental
    Zovegalisib + fulvestrant

    Zovegalisib + fulvestrant combination for participants with HR+/HER2- advanced breast cancer

    Drug: Zovegalisib · Drug: Fulvestrant

  • Active comparator
    capivasertib + fulvestrant

    capivasertib + fulvestrant combination for participants with HR+/HER2- advanced breast cancer

    Drug: Capivasertib · Drug: Fulvestrant

Interventions

  • DrugZovegalisib

    400 mg orally BID administered daily on a 28-day treatment cycle

  • 400mg orally BID administered on an intermittent weekly dosing schedule. Patients will dose on Days 1 through 4 each week of a 28-day treatment cycle

    Also known as: TRUQAP

  • 500 mg intramuscularly administered on Cycle 1 Day 1, Day 15, and Day 1 of each subsequent cycle (28-day treatment cycle)

    Also known as: Faslodex

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) within the overall and kinase population by blinded independent central review (BICR)

    Time frame: The time from date of randomization until radiographic progression per RECIST v1.1, or death due to any cause, up to approximately 77 months

Secondary outcomes

  1. Overall Survival (OS) within the overall and kinase populations

    Time frame: The time from randomization to the date of death by any cause, up to approximately 77 months

  2. PFS by Investigator within the overall and kinase populations

    Time frame: The time from date of randomization until radiographic progression per RECIST v1.1, or death due to any cause, up to approximately 77 months

  3. Objective Response Rate (ORR) within the overall and kinase populations

    Time frame: Up to approximately 77 months

  4. Duration of Response (DOR) within the overall and kinase populations

    Time frame: Up to approximately 77 months

  5. Clinical Benefit Rate (CBR) within the overall and kinase populations

    Time frame: Up to approximately 77 months

  6. Occurrence/frequency of Adverse Events (AEs) and its relationship to the study drugs (safety and tolerability) within the overall and kinase populations

    Time frame: Up to approximately 77 months

  7. Plasma concentrations of zovegalisib (and its metabolites as appropriate)

    Time frame: Approximately every 2 weeks in Cycle 1 (4-week cycle) and during Cycles 2 and 3

  8. European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30) scale/item scores including change from baseline and time to deterioration within overall and kinase populations

    Time frame: Up to approximately 77 months

  9. EORTC Quality of Life Questionnaire Breast Cancer-Specific Module (EORTC QLQ-BR23) scale/item scores including change from baseline and time to deterioration within the overall and kinase populations

    Time frame: Up to approximately 77 months

  10. Health state utility data for economic evaluation by EQ-5D-5L health state utility index within the overall and kinase populations

    Time frame: Up to approximately 77 months

07

Study locations

254 of 254 sites recruiting

Showing the first 100 of 254 sites across 27 countries. Choose a country and city above to see the rest.

08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Apr 2028, 32 months after the start.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's planned 32 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2025
First posted
May 21, 2025
StartActual
Aug 26, 2025
Primary completionEst.
Apr 30, 2028
CompletionEst.
Dec 31, 2031
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
23 sites added — first sites in Ireland, Romania and Turkey (Türkiye)
Show 23 added (6 Romania, 4 Turkey (Türkiye), 3 Spain, 3 United Kingdom, 2 Germany, 1 Czechia, 1 Ireland, 1 Poland, 1 Portugal, 1 France)
  • Fakultni Nemocnice v Motole · Prague, Czechia
  • Universitaetsklinikum Freiburg · Freiburg im Breisgau, Germany
  • Beaumont Hospital · Dublin, Ireland
  • Centrum Onkologii Ziemi Lubelskiej · Lublin, Poland
  • Unidade Local de Saúde de Matosinhos, E.P.E. - Hospital Pedro Hispano · Matosinhos Municipality, Portugal
  • Oncolab SRL · Craiova, Romania
  • Victoria Hospital SRL · Iași, Romania
  • Asociatia Oncohelp · Timișoara, Romania
  • Hospital Universitario Virgen de Macarena · Seville, Spain
  • Dicle University Hospital · Sur, Turkey (Türkiye)
  • Guy's and St. Thomas' NHS Foundation Trust · London, United Kingdom
  • Nottingham University Hospital NHS Trust · Nottingham, United Kingdom
  • Centre Georges François Leclerc · Dijon, France
  • Universitätsklinikum Aachen AÖR · Aachen, Germany
  • Institutului Oncologic Prof. Dr. Ion Chiricuță · Cluj-Napoca, Romania
  • Centrul de Oncologie Sfantul Necatarie Craiova · Craiova, Romania
  • S.C Radiotherapy Center Cluj S.R.L · Floreşti, Romania
  • Hospital General Universitario Gregorio Maranon · Madrid, Spain
  • Hospital Clinico San Carlos · Madrid, Spain
  • Memorial Ankara Hospital · Ankara, Turkey (Türkiye)
  • Istinye University Liv Hospital Topkapı · Istanbul, Turkey (Türkiye)
  • Kocaeli University Medical Faculty Hospital · Kocaeli, Turkey (Türkiye)
  • Musgrove Park Hospital, Somerset NHS Foundation Trust · Taunton, United Kingdom
across 2 updates, Oct 5, 2026 – Nov 5, 2026
Show all 2 updates
  1. Nov 5, 2026
    11 sites added
    Show 11 added (3 Romania, 3 Turkey (Türkiye), 2 Spain, 1 France, 1 Germany, 1 United Kingdom)
    • Centre Georges François Leclerc · Dijon, France
    • Universitätsklinikum Aachen AÖR · Aachen, Germany
    • Institutului Oncologic Prof. Dr. Ion Chiricuță · Cluj-Napoca, Romania
    • Centrul de Oncologie Sfantul Necatarie Craiova · Craiova, Romania
    • S.C Radiotherapy Center Cluj S.R.L · Floreşti, Romania
    • Hospital General Universitario Gregorio Maranon · Madrid, Spain
    • Hospital Clinico San Carlos · Madrid, Spain
    • Memorial Ankara Hospital · Ankara, Turkey (Türkiye)
    • Istinye University Liv Hospital Topkapı · Istanbul, Turkey (Türkiye)
    • Kocaeli University Medical Faculty Hospital · Kocaeli, Turkey (Türkiye)
    • Musgrove Park Hospital, Somerset NHS Foundation Trust · Taunton, United Kingdom
  2. Oct 5, 2026
    12 sites added — first sites in Ireland, Romania and Turkey (Türkiye)
    Show 12 added (3 Romania, 2 United Kingdom, 1 Czechia, 1 Germany, 1 Ireland, 1 Poland, 1 Portugal, 1 Spain, 1 Turkey (Türkiye))
    • Fakultni Nemocnice v Motole · Prague, Czechia
    • Universitaetsklinikum Freiburg · Freiburg im Breisgau, Germany
    • Beaumont Hospital · Dublin, Ireland
    • Centrum Onkologii Ziemi Lubelskiej · Lublin, Poland
    • Unidade Local de Saúde de Matosinhos, E.P.E. - Hospital Pedro Hispano · Matosinhos Municipality, Portugal
    • Oncolab SRL · Craiova, Romania
    • Victoria Hospital SRL · Iași, Romania
    • Asociatia Oncohelp · Timișoara, Romania
    • Hospital Universitario Virgen de Macarena · Seville, Spain
    • Dicle University Hospital · Sur, Turkey (Türkiye)
    • Guy's and St. Thomas' NHS Foundation Trust · London, United Kingdom
    • Nottingham University Hospital NHS Trust · Nottingham, United Kingdom

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06982521
Lead sponsor
Relay Therapeutics, Inc.
Responsible party
Sponsor
First posted
May 21, 2025
Start date
Aug 26, 2025
Primary completion
Apr 30, 2028 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Nov 5, 2026

Study contacts

Relay Therapeutics, Inc
Contact
ClinicalTrials@relaytx.com
617-322-0731

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion